Use of the abatacept in a patient with psoriatic arthritis.

Authors:
  • CRCarlos Ewerton Maia Rodrigues
    Carlos Ewerton Maia Rodrigues
  • FVFrancisco José Fernandes Vieira
    Francisco José Fernandes Vieira
  • MCMaria Roseli Monteiro Callado
    Maria Roseli Monteiro Callado
  • JAJosé Eyorand Castelo Branco De Andrade
    José Eyorand Castelo Branco De Andrade
  • WVWalber Pinto Vieira
    Walber Pinto Vieira

  • 3 December 2010
    • journal article
    • case report
Abstract
Psoriatic arthritis (PA) is an inflammatory seronegative arthritis of unknown origin. Classically, PA has five clinical forms, and asymmetric oligoarthritis is the most common type. We describe the case of a patient with PA refractory to disease-modifying drugs, who developed drug-induced hepatitis after chemoprophylaxis with isoniazid, administered prior to the treatment with an anti-TNFα agent. Due to the risk of activating latent tuberculosis with the administration of anti-TNFα and hepatotoxicity onset caused by the TB treatment and based on the fact that the treatment of PA is similar to the treatment of rheumatoid arthritis, a decision was made to use the empirical treatment with abatacept. Approximately twenty days after the second infusion of the drug, the patient showed clinical improvement, resolution of the arthritis, almost complete disappearance of the skin lesions and improvement of anemia and inflammatory tests.